In 2011 the Group generated more gross revenue from outside South Africa than from inside South Africa. It is likely to be the last year in which the South African business contributes more than half of operating profits.
||EBITA represents operating profit before taking into account the following items: amortisation, capital component of insurance compensation, transaction costs, restructuring costs, impairment of assets and profit on sale of non-current assets.
The increasing diversity of profit sources for Aspen provides considerable mitigation against individual country risk, be that political, economic, regulatory, social or currency risk.
Independent assessments of the growth drivers in global pharmaceutical markets through to 2015 place the emerging markets and generics as the material drivers of growth. This fits well with the Group’s positioning both from a market focus, and also from the perspective of product emphasis.